AI주식인사이트AI Stock Insight
C

엔지켐생명과학

183490KOSDAQ기초 의약물질 제조업

46.8 / 100

Reference Date: 2026-07-24

Financial Score23.0 / 40
News Sentiment18.8 / 25
Momentum5.0 / 20
Disclosure0.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Enzychem Life Sciences focuses on global new drug development, API manufacturing, health functional foods, and bio-oil production. The company is advancing the development of EC-18, a treatment for chemotherapy-induced oral mucositis, and expanding into AI-driven drug discovery and DAC technology. Its API division exports over 40 products globally, while its health functional food segment offers immune-supporting products like 'LockFeed Immune'.

Number of Employees

116people

Average Salary

48.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 25.444.0Point
PBR
0.60Industry Average 1.267.0Point

Half of industry avg (excellent)

ROE
-12.05Industry Average -6.033.5Point

2.0x industry avg (good)

Debt Ratio
1.15Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼5.3% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼0.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -9.7% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 1Neutral 0Negative 1Average Sentiment Score 75

Detailed Momentum

52-week position1.0Point

Near 52w low (3%, downtrend)

Current 990Won52-week high 1,69952-week low 968
1-month return3.0Point

1m 0% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

16 totalPositive 0Neutral 9Negative 7
  • Neutral임시주주총회결과2026-07-23
  • Neutral독립이사의선임ㆍ해임또는중도퇴임에관한신고2026-07-23
  • Negative[기재정정]소송등의판결ㆍ결정 (경영권 분쟁 소송)(검사인 선임)2026-07-23
  • Negative소송등의판결ㆍ결정 (임시주주총회개최금지 가처분)2026-07-23
  • Negative소송등의판결ㆍ결정 (주주명부열람등사가처분)2026-07-21